KEYNOTE-522: Neoadjuvant KEYTRUDA® (pembrolizumab) plus chemotherapy followed by adjuvant pembrolizumab monotherapy in patients with triple-negative breast cancer (TNBC)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

The KEYNOTE-522 Data animation provides an overview of the primary end points, efficacy, and safety data from the KEYNOTE-522 clinical trial “Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer”. Watch the video to hear Professor Peter Schmid, the principal investigator of the trial, talk through its primary analyses and 60-month follow-up data.

Length: 07:32
KEYNOTE-522 Study Design: 01:19
KEYNOTE-522 Primary analyses: 01:50
KEYNOTE-522 Exploratory analysis at 60-month follow up: 03:20
Summary: 06:32

KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.¹

KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease.¹

Please refer to the SmPC for further information before making any prescribing decisions.

For more information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC), click on the product page button below:

Reference

1. KEYTRUDA Summary of Product Characteristics

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website